Treatment with the BTK inhibitor evobrutinib (Merck KGaA) dose-dependently inhibited maturation of B-cells, antigen-triggered activation and the release of pro-inflammatory cytokines in animal models of MS. Here, BTK is linked to myeloid sarcoma.